4 completed, 2 terminated. 2 Phase 1, 2 Phase 3, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 2 | Terminated 2 |
| Phase 2 | 1 | Completed 1 |
Follow morphine, naltrexone combination: new trials by email Literature Review of morphine, naltrexone combination trials Research Report on morphine, naltrexone combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride) - Nondependent Opioid Abuse, Episodic | Phase 1 | Completed | Pfizer | 80 | 2011-02-01 | 2012-05-31 |
| Conversion to Embeda With Rescue Trial morphine sulfate and naltrexone hydrochloride (EMBEDA) - Chronic Disease, Pain | Phase 4 | Terminated | Pfizer | 684 | 2010-08-01 | 2012-10-11 |
| Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole - Chronic Pain | Phase 4 | Terminated | Pfizer | 14 | 2010-04-01 | 2012-07-13 |
| Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR) ALO-01, MSIR, Placebo - Healthy | Phase 1 / Phase 2 | Completed | Pfizer | 32 | 2007-03-01 | 2013-09-16 |
| A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo - Osteoarthritis, Chronic Pain | Phase 3 | Completed | Pfizer | 547 | 2006-12-01 | 2013-09-20 |
| Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER) - Pain | Phase 3 | Completed | Pfizer | 467 | 2006-12-01 | 2013-09-20 |
Chronic Pain (4) · Pain (3) · Arthralgia (1) · Back Pain (1) · Chronic Disease (1) · Neuralgia, Postherpetic (1) · Osteoarthritis (1) · Pressure Ulcer (1) · Recurrence (1) · Substance Withdrawal Syndrome (1)
Pfizer (6)
United States (5) · Canada (1)
James B. Jones, MD, PharmD (2) · Myroslav Romach, MSC, MD (1)
PMID 26695349, PMID 21075272, PMID 21904098, PMID 23709323, PMID 23745947, PMID 26185466, PMID 27782769